Re: Dehydroepiandrosterone supplementation has no added benefit on live birth rate in poor ovarian responders.

Szczegóły
Comments

Tytuł:: Re: Dehydroepiandrosterone supplementation has no added benefit on live birth rate in poor ovarian responders.
Autorzy:: Sethi A; Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Singh N; Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Patel G; Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.
Źródło:: BJOG : an international journal of obstetrics and gynaecology [BJOG] 2022 Aug; Vol. 129 (9), pp. 1610. Date of Electronic Publication: 2022 Apr 03.
Typ publikacji:: Letter; Comment
Język:: English
Imprint Name(s):: Publication: : Oxford : Wiley-Blackwell
Original Publication: Oxford [England] : Blackwell Science, [2000]-
MeSH Terms:: Birth Rate*
Infertility, Female*
Dehydroepiandrosterone/therapeutic use ; Dietary Supplements ; Female ; Fertilization in Vitro ; Humans ; Live Birth ; Ovulation Induction ; Pregnancy ; Pregnancy Rate
References:: Wang Z, Yang A, Bao H, Wang A, Deng X, Xue D, et al. Effect of dehydroepiandrosterone administration before in vitro fertilization on the live birth rate in poor ovarian responders according to the Bologna criteria: a randomised controlled trial. BJOG. 2021. https://doi.org/10.1111/1471-0528.17045.
Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452-3.
The ESHRE Guideline Group on Ovarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Human Reprod Open. 2020;2020(2):hoaa009.
JOINT SOGC-CFAS. Guidelines for the number of embryos to transfer following in vitro fertilization No. 182, September 2006. Int J Gynecol Obstet. 2008;102(2):203-16.
Substance Nomenclature:: 459AG36T1B (Dehydroepiandrosterone)
Entry Date(s):: Date Created: 20220404 Date Completed: 20220712 Latest Revision: 20220713
Update Code:: 20240105
DOI:: 10.1111/1471-0528.17159
PMID:: 35373428
: Opinia redakcyjna

Full Text Finder

Comment on: BJOG. 2022 Jun;129(7):1030-1038. (PMID: 34882964)
Comment in: BJOG. 2022 Aug;129(9):1611. (PMID: 35384235)

Informacja